Publication: Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: A randomized trial at Ramathibodi Hospital
Issued Date
2002-11-01
Resource Type
ISSN
01252208
Other identifier(s)
2-s2.0-0036881880
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.85, No.SUPPL. 4 (2002)
Suggested Citation
Sarayut Supapannachart, Anchalee Limrungsikul, Pongsak Khowsathit Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: A randomized trial at Ramathibodi Hospital. Journal of the Medical Association of Thailand. Vol.85, No.SUPPL. 4 (2002). Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/20323
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Oral ibuprofen and indomethacin for treatment of patent ductus arteriosus in premature infants: A randomized trial at Ramathibodi Hospital
Other Contributor(s)
Abstract
Background: Ibuprofen given intravenously to premature newborn infants is a proven treatment for patent ductus arteriosus (PDA). The efficacy of ibuprofen is comparable to indomethacin in many clinical trials with fewer renal side effects. However, the intravenous form of ibuprofen is not available in Thailand, whereas, the oral suspension form is widely used for antipyretic treatment in children. Therefore, the authors investigated the possibilities of using oral ibuprofen for the treatment of PDA in premature newborn infants. Objective: To assess whether oral ibuprofen at 10 mg/kg/dose daily for 3 days was as effective as indomethacin to treat symptomatic PDA in premature infants and to compare the side effects of oral ibuprofen to indomethacin. Subjects and Method: Eighteen premature infants with gestational ages less than 34 weeks born at Ramathibodi Hospital who developed symptomatic PDA were randomly assigned to receive three doses of either indomethacin (oral or intravenous administration 0.2 mg/kg/dose for three doses given at 12 hourly intervals or oral ibuprofen (10 mg/kg/dose for three doses given at 24 hourly intervals). The rates of ductal closure, infants' clinical courses, side effects and complications were recorded. Results: Birth weight, gestational age, gender, age onset and number of infants who had respiratory distress syndrome were similar in both groups, PDA was closed in 7 of 9 infants given ibuprofen (78%) and in 8 of 9 infants given indomethacin (89%) (p>0.05). The mean plasma concentration of ibuprofen was 28.05 μg/ml at 1 hour after the third dose. Neonates in the ibuprofen group had more urine output. However, the increment of serum BUN and creatinine were not significantly different in both groups. There were no significant differences in duration of ventilator support as well as number of patients with bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis and death in both groups. Conclusion: Oral ibuprofen therapy is as effective as indomethacin for the treatment of PDA in premature infants and seems to have fewer renal side effects.